Evaluation of p53 protein expression in renal cell carcinoma: Comparison of two antibodies

British Journal of Biomedical Science

Volumn 53, Issue 3, 1996, Pages 179-181

  Barry Walsh, C J ^a   Kay, E W ^a   Lynch, T ^a   Walsh, M ^a   Milburn, C ^a   Mclean, P A ^a   Murphy, D ^a   Donovan, M ^a   Leader, M B ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Immunohistochemistry; p53; Renal cell carcinoma

Indexed keywords

FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; POLYCLONAL ANTIBODY; PROTEIN P53;

ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 0029845999     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Harris AL. Mutant p53 - the commonest genetic abnormality in human cancer.J Pathol 1990; 162:5-6.
2. Lane DP. p53 - guardian of the genome. Nature 1992; 358:15-16.
3. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer 1988; 41:178-83.
4. Dowell SP, Hall PA. The clinical relevance of the p53 tumour suppressor gene. Cytopathology 1994; 5:133-45.
5. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphological parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655-63.